Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) EPS (Weighted Average and Diluted) (2020 - 2025)

Precision Biosciences (DTIL) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$1.84 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 28.96% to -$1.84 in Q3 2025 year-over-year; TTM through Sep 2025 was -$8.92, a 24.28% increase, with the full-year FY2024 number at $1.04, up 106.52% from a year prior.
  • EPS (Weighted Average and Diluted) was -$1.84 for Q3 2025 at Precision Biosciences, up from -$2.13 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $4.67 in Q2 2024 to a low of -$37.43 in Q4 2022.
  • A 5-year average of -$4.02 and a median of -$1.84 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 9750.0% in 2022, then soared 4770.0% in 2024.
  • Precision Biosciences' EPS (Weighted Average and Diluted) stood at -$0.38 in 2021, then plummeted by 9750.0% to -$37.43 in 2022, then soared by 58.43% to -$15.56 in 2023, then skyrocketed by 82.39% to -$2.74 in 2024, then surged by 32.85% to -$1.84 in 2025.
  • Per Business Quant, the three most recent readings for DTIL's EPS (Weighted Average and Diluted) are -$1.84 (Q3 2025), -$2.13 (Q2 2025), and -$2.21 (Q1 2025).